EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy

Tiancheng Li, Mimi Xu, Shuye Yang, Guolin Wang, Yinuo Liu, Kaifeng Liu, Kui Zhao, Xinhui Su iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024-07 · 51 (9) · 2806-2818

DOI: 10.1007/s00259-024-06734-6 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 01.05.2024. Verfasst von Tiancheng Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, People's R…. Hauptthemen laut MEDLINE: Prostatectomy, Prostatic Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Biochemical recurrence (BCR) following radical prostatectomy (RP) is a significant concern for patients with prostate cancer. Reliable prediction models are needed to identify patients at risk for BCR and facilitate appropriate management. This study aimed to develop and validate a clinical-radiomics model based on preoperative [18 F]PSMA-1007 PET for predicting BCR-free survival (BRFS) in patients who underwent RP for prostate cancer. MATERIALS AND METHODS: A total of 236 patients with histologically confirmed prostate cancer who underwent RP were retrospectively analyzed. All patients had a preoperative [18 F]PSMA-1007 PET/CT scan. Radiomics features were extracted from the primary tumor region on PET images. A radiomics signature was developed using the least absolute shrinkage and selection operator (LASSO) Cox regression model. The performance of the radiomics signature in predicting BRFS was assessed using Harrell's concordance index (C-index). The clinical-radiomics nomogram was constructed using the radiomics signature and clinical features. The model was externally validated in an independent cohort of 98 patients. RESULTS: The radiomics signature comprised three features and demonstrated a C-index of 0.76 (95% CI: 0.60-0.91) in the training cohort and 0.71 (95% CI: 0.63-0.79) in the validation cohort. The radiomics signature remained an independent predictor of BRFS in multivariable analysis (HR: 2.48, 95% CI: 1.47-4.17, p < 0.001). The clinical-radiomics nomogram significantly improved the prediction performance (C-index: 0.81, 95% CI: 0.66-0.95, p = 0.007) in the training cohort and (C-index: 0.78 95% CI: 0.63-0.89, p < 0.001) in the validation cohort. CONCLUSION: We developed and validated a novel [18 F]PSMA-1007 PET-based clinical-radiomics model that can predict BRFS following RP in prostate cancer patients. This model may be useful in identifying patients with a higher risk of BCR, thus enabling personalized risk stratification and tailored management strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstatectomyProstatic NeoplasmsPositron Emission Tomography Computed TomographyHumansMaleMiddle AgedAgedRetrospective StudiesOligopeptidesDisease-Free SurvivalImage Processing, Computer-AssistedRadiomicsNiacinamide

Stichwörter der Autor:innen

BRFSClinical-radiomics modelProstate cancer[18F]PSMA-1007 PET/CT

Substanzen

PSMA-1007OligopeptidesNiacinamide

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, People's Republic of China.
  • Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, People's Republic of China. suxinhui@zju.edu.cn.

ORCID-Profile: Xinhui Su

Zitieren

APA

Li, T., Xu, M., Yang, S., Wang, G., Liu, Y., Liu, K., Zhao, K., & Su, X. (2024). Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 51(9), 2806-2818. https://doi.org/10.1007/s00259-024-06734-6

Vancouver

Li T, Xu M, Yang S, Wang G, Liu Y, Liu K, et al. Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(9):2806-2818. doi:10.1007/s00259-024-06734-6

BibTeX
@article{Li2024,
  author = {Li, Tiancheng and Xu, Mimi and Yang, Shuye and Wang, Guolin and Liu, Yinuo and Liu, Kaifeng and Zhao, Kui and Su, Xinhui},
  title = {Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {51},
  number = {9},
  pages = {2806--2818},
  doi = {10.1007/s00259-024-06734-6}
}
Kostenlos starten →